In April 2026, the FDA began moving seven peptides off its most restrictive compounding list and toward formal review. The change does not make these peptides approved drugs, and the decision that matters most has not happened yet. A federal advisory committee meets in July 2026 to recommend whether peptides like BPC-157 should be legal to compound. Here is what changed, what the categories mean, and what to expect next.
On April 23, 2026, the FDA removed seven peptides from its restrictive Category 2 compounding list. On its own, this was a procedural step: the peptides came off one list, but they were not added to another. In practice it moved away from the 2023 restrictions that had stopped compounding pharmacies from preparing peptides such as BPC-157 and TB-500.
The more important date is still ahead. The Pharmacy Compounding Advisory Committee meets on July 23 and 24, 2026, to decide whether these peptides should be eligible for compounding. That recommendation, not the April removal, will shape what peptide therapy looks like for the next several years.
The FDA’s 503A compounding system sorts bulk drug substances into three categories. Those categories decide what a licensed compounding pharmacy can legally prepare for a patient.
| Category | Status | What it means |
|---|---|---|
| Category 1 | Eligible | Sufficient supporting data. The FDA allows compounding while it completes its evaluation. |
| Category 2 | Ineligible | The FDA has identified significant safety risks. Not authorized for compounding. |
| Category 3 | Ineligible | Insufficient data for the FDA to begin a full evaluation. |
In September 2023, the FDA placed 19 peptides into Category 2, citing immunogenicity concerns, limited human safety data, and contamination risks. Compounding pharmacies had to stop preparing them, and many patients turned to an unregulated gray market.
On April 16, 2026, the FDA announced that the Category 2 applications for seven of those peptides had been withdrawn. The April 23 removal followed. The seven peptides are now in regulatory gray space: not banned, not authorized. Compounding pharmacies stay in a period of uncertainty until the advisory committee meets in July.
The Pharmacy Compounding Advisory Committee will meet for two days in Silver Spring, Maryland to review whether seven peptides should be added to the 503A bulks list. A peptide on that list has clear legal status for compounding.
On July 23, the committee reviews BPC-157, KPV, TB-500, and MOTS-c. On July 24, it reviews Emideltide (also called DSIP), Semax, and Epitalon. The deadline for public comments is July 9, 2026. If the committee recommends inclusion, the FDA publishes new regulations and compounding becomes legal. If it does not, the peptides stay in gray space. Details are posted on the FDA’s page for the Pharmacy Compounding Advisory Committee meeting on July 23 and 24, 2026.
A second committee meeting is scheduled before the end of February 2027 to review five more peptides, including GHK-Cu, Cathelicidin, Dihexa, Melanotan II, and mechano growth factor, per an April 2026 Federal Register notice.
All seven peptides were placed in Category 2 in 2023 for similar reasons: limited human safety data, immunogenicity concerns, and contamination risks. The committee will weigh whether those concerns can be managed.
The category lists matter because they govern the pharmacies that prepare your medication. Body Works works with two types of compounding pharmacy.
A 503A pharmacy prepares medications for a specific patient based on a prescription from a licensed provider. A 503B outsourcing facility prepares larger batches for in-office use. Both operate under the FDA’s human drug compounding program and its federal standards.
The safety risk with peptides usually comes less from the peptide itself than from where it is made. A licensed compounding pharmacy must document every ingredient and test for purity, potency, and sterility. Unregulated online sellers follow none of these rules, which is why a peptide bought from an unknown website is a gamble on what the vial actually contains.
Until the advisory committee meets and the FDA publishes new rules, nothing changes for patient access. The peptides under review are still best approached through a licensed medical provider who can source from quality compounding pharmacies. The same caution applies to sourcing in general, a point covered in our guide on why authenticity matters with peptides.
At Body Works, peptide therapy follows a defined process:
Regulatory access on its own does not make peptide therapy safe. It helps only when it is paired with physician oversight and quality compounding. That is the difference between a peptide prescribed and monitored by a licensed provider and one bought from an unregulated supplier. You can review the current options on the Body Works peptide therapy page.
Until the committee votes and the FDA publishes new rules, patient access does not change. If you are considering peptide therapy now, work with a licensed provider who can navigate the current rules and source responsibly.
The regulatory picture for peptides is still in motion, but the clinical standard has not changed. The safest path is the same one it has always been: a licensed medical team, real lab work, and compounding pharmacies that meet federal quality standards.
Body Works offers peptide therapy designed around specific health goals, with physician oversight and responsible sourcing at every step. Whether you visit the office in Franklin or Nolensville, the goal is the same: a plan built for your body, not a guess.
Schedule a Free Consultation to discuss whether peptide therapy fits your goals and what the current rules mean for your options.
Medically reviewed by Dr. Donald Vollmer, MD
Managing Physician, Body Works TN
A lot of what passes for testosterone replacement therapy in Franklin, TN and nationwide in 2026 is a questionnaire, a card swipe, and a prescription
A symptom that is completely normal in week two can be a reason to call your prescriber in week fourteen. Nausea right after a dose
All three of these show up in the same conversation, usually because someone read that they all “boost growth hormone” and assumed that made them
GLP-1 nausea affects 44% of semaglutide patients and 25% to 29% on tirzepatide, clusters around dose increases, and fades within weeks for most. Smaller meals,
Searching for semaglutide in a town the size of Nolensville turns up a strange gap: national telehealth ads everywhere, but almost nothing about a real
If you have been researching semaglutide for weight loss, you have probably hit the same wall everyone else does: a telehealth app that ships a
See Body Works first in your Google results.
